Arxis ARXS 深 沪
等待开盘 08-20 09:30:00 美东时间
55.71
-0.850
-1.50%
华盛通- 最 高57.28
- 今 开57.28
- 成交量 43.38万股
- 最 低 54.74
- 昨 收 56.56
- 总市值 232.57亿
- 52周最高 61.50
- 市盈率 静 496.97
- 换手率 0.10%
- 52周最低 33.15
- 委 比 -98.17%
- 总股本 4.17亿
- 历史最高 61.50
- 量 比 0.77
- 振 幅 4.49%
- 历史最低 33.15
- 每 手 1
- 风险率 7.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股盘后 | 诺福克南方上升3.08%，Keysight Technologies Inc上升2.98%
诺福克南方上升3.08%；Keysight Technologies Inc上升2.98%；洛斯公司小升1.93%
08-19 06:10
Arxis Completes the Acquisition of Omnetics Connector Corporation
BLOOMFIELD, Conn., Aug. 18, 2026 /PRNewswire/ -- Arxis, Inc. (NASDAQ: ARXS) (the "Company" or "Arxis"), a publicly traded industrial compounder formed in partnership with Arcline Investment ...
08-18 20:15
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Citigroup Maintains Buy on Arxis, Raises Price Target to $67
Citigroup analyst John Godyn maintains Arxis (NASDAQ:ARXS) with a Buy and raises the price target from $61 to $67.
08-14 03:09
Defense tech firm Lyntris targets $2.53B valuation in US IPO
Lyntris (LYNX) is targeting a valuation of up to $2.53B in its U.S. initial public offering, as the Trive Capital-backed firm seeks to capitalise on strong investor demand for defense listings. The of...
08-10 20:51
美股大行评级 | Palantir、Snap、爵士制药获多家大行上调目标价；潜在涨幅176.34%！巴克莱维持Snap(SNAP)"超配"评级，目标价从15美元上调至16美元
今日重点评级关注：巴克莱：维持Snap"超配"评级，目标价从15美元升至16美元；Canaccord Genuity：维持阿梅雷斯克"买入"评级，目标价从59美元升至62美元
08-05 11:45
美股大行评级 | 最高400美元！亚马逊绩后获11家大行上调目标价；苹果绩后评级分歧大！3家上调，3家下调；德康医疗、万事达、神经分泌生物科学获多家大行上调目标价
今日重点评级关注：TD Cowen：维持加拿大鹅"买入"评级，目标价从13美元升至18美元；瑞银：维持吉登运动服"买入"评级，目标价从110美元升至111美元
08-03 11:38
Citigroup Maintains Buy on Arxis, Raises Price Target to $61
Citigroup analyst John Godyn maintains Arxis (NASDAQ:ARXS) with a Buy and raises the price target from $54 to $61.
08-01 04:23
Arxis shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
Arxis shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
07-30 04:29
Arxis Raises FY2026 Sales Guidance from $1.860B-$1.880B to $1.960B-$1.980B vs $1.883B Est
Arxis (NASDAQ:ARXS) raises FY2026 sales outlook from $1.860 billion-$1.880 billion to $1.960 billion-$1.980 billion vs $1.883 billion estimate.
07-30 04:14
